Osivax
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
70 Rue Saint Jean Dieu, Lyon, Auvergne-R...Phone Number
+33 970301380Website
www.osivax.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Osivax
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses.Osivax’s ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Osivax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Osivax is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Osivax
Check if Osivax has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Osivax, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Osivax has new funding data
Click to see if Osivax had a recent Job posting/layoffs
Product Launch: Get notified when Osivax launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Osivax recently announced quarterly report
Recommended Actions
Find VP level buyers at Osivax
Find 2 more new buyers
Company Profile Activity
Activity Insights
Osivax is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Osivax is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Osivax.
Osivax financials insights
Gather financial insights about Osivax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$6.5M
Series A
$8.8M
2025
Series B
$10.8M
Other Financing Round
$19.5M
Osivax Tech Stack
A closer look at the technologies used by Osivax
See more technologies
Most Recent Scoops
Person-Based
Funding
Funding
Person-Based
Person-Based
Funding
Funding
Osivax News & Media
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836
Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its Phase 2b clinical trial (NCT05569239) evaluating OVX836, the company’s broad-spectrum influenza A vaccine candidate.Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has secured $19.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The multi-year agreement will support key devOsivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of positive results from its Phase 2a, OVX836-004, study in the journal Vaccines. The study evaluated the safety and immunogenicity of co-administering OVX836, Osivax’ broad-spectrum influenza vaccine candidate, with the hemagglutinin antigen (HA)-based inactivated influenza vaccine Fluarix® Tetra.Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release
Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Osivax
Sign Up For FreeTo access detailed company insights
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses.Osivax’s ambition is to develop a pan-respiratory... Read More
